Loading clinical trials...

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant | Clinical Trials | Clareo Health

COMPLETED

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

A Non-interventional, Observational Qualitative Interview Study of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

NCT07008963•AstraZeneca

View on ClinicalTrials.gov

Summary

A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult (over the age of 18 years)
•Diagnosed with HR+/HER2- metastatic breast cancer
•Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation)

Exclusion Criteria

•Patients who had discontinued capivasertib for more than 6 months before the date of the interview
•Unable or unwilling to follow study procedures (including providing informed consent)
•Not proficient in spoken English, as assessed by the moderator
•Receiving capivasertib in a clinical trial setting
•Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)

Locations (1)

Research Site

Redwood Shores, California, United States

Key Dates

Start Date

July 31, 2025

Primary Completion Date

November 28, 2025

Completion Date

November 28, 2025

Last Updated

February 23, 2026

Enrollment

ACTUAL participants

Conditions

Metastatic Breast Cancer

Interventions

non-interventional

OTHER

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

Solid Tumor, AdultMetastatic Breast Cancer+9 more

View study

RECRUITINGPHASE2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

NCT06649331

Advanced Breast CancerMetastatic Breast Cancer+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

Inclusion Criteria

Exclusion Criteria

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

A Study of Surgery and Radiotherapy in People With Breast Cancer